Project Grant R43CA171388

Federal Project Grant Award Summary Oncotab, Inc. received a $1,130,587 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) awarded August 1, 2026, with completion targeted for July 31, 2028. This Phase II Small Business Innovation Research (SBIR) award supports preclinical development of MUCD3, a bispecific antibody T-cell engager designed to treat pancreatic cancer. The project advances MUCD3 through critical de-risking studies...

This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $338,828 to Bioplatinum Technologies LLC to study the effects of new platinum anticancer drugs in pancreatic cancer. The project aims to exploit the high levels of chondroitin-4-sulfate (C4S) glycosaminoglycans in pancreatic tumors to enhance the delivery and efficacy of the polynuclear platinum complex (PPC) drug triplatin. The research will evaluate triplatin as a potential...

Federal Cooperative Agreement Summary The National Cancer Institute awarded a $2,054,733 Cooperative Agreement to Massachusetts General Hospital's Research Management Division, effective September 1, 2025 through August 31, 2028, under the Cancer Treatment Research program (CFDA 93.395). The award supports the development and optimization of novel chimeric antigen receptor (CAR) T cell therapy for pancreatic cancer, specifically advancing MESO-FAP CAR-TEAM cells that simultaneously target...

Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $109,080 to The Trustees of Columbia University in the City of New York (Health Sciences Division) on September 1, 2025, under the Cancer Research Manpower program (CFDA 93.398) to support a Phase II investigator-initiated, multicenter randomized controlled trial (RCT) evaluating predictive markers of response to a novel immunotherapeutic approach in treatment-naive metastatic pancreatic adenocarcinoma (MPDA). The...

Paramita Therapeutics Inc. received a $353,009 Phase I Small Business Innovation Research (SBIR) grant from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395), awarded September 24, 2025, with completion targeted for August 31, 2026. The project focuses on developing novel multivalent prostate-specific membrane antigen (PSMA)-targeted taxane-conjugates to address bone metastases in prostate cancer. The research involves synthesizing multivalent drug conjugates (MDCs)...

The National Cancer Institute awarded Columbia University's Health Sciences Division a $683,970 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective April 1, 2026 through March 31, 2031. This grant funds research on tumor-penetrating stromal modification in pancreatic ductal adenocarcinoma (PDAC) targeting the αvβ5 integrin pathway. The research investigates the IRGD tumor-penetrating peptide's ability to inhibit αvβ5-mediated transforming growth factor-beta...

Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant totaling $482,236 to Sloan-Kettering Institute for Cancer Research under the Cancer Treatment Research program (CFDA 93.395) on August 1, 2025, with a project completion date of July 31, 2030. This investigator-initiated Phase 2 clinical trial will evaluate the safety and efficacy of combining trastuzumab deruxtecan (T-DXD), an antibody-drug conjugate, with the anti-EGFR (epidermal growth factor receptor)...

Summary The National Cancer Institute awarded The Methodist Hospital Research Institute a $415,257 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) on June 9, 2026, to develop image-guided adaptable chimeric antigen receptor (CAR) T cell therapy for solid tumors. The project addresses critical limitations in current CAR T cell treatments, including tumor relapse, antigen escape, T cell exhaustion, and severe toxicities. The research will create a universal,...

Federal Project Grant Award Summary Emory University's Office of Sponsored Programs received a $602,170 Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394) awarded June 2, 2026, with completion targeted for May 31, 2031. The research develops biomimetic migrating nanoparticles designed to target tumor stroma and neural invasion in pancreatic cancer treatment while reducing neuropathic pain. The core innovation involves a...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $799,962 to Tripill Biotechnology, Corp. to develop radiolabeled PSMA agents with low salivary gland uptake for improved prostate cancer imaging and therapy. The key products and services to be delivered include: Constructing PSMA derivative compounds, such as NOTA-UNC-PSMA2, that can selectively reduce salivary gland uptake while maintaining high tumor uptake in prostate...